XTL BiopharmaceuticalsXTLB
13F holders, Q4 2024 (December 31)3holders
0new positions
0sold out
$2.03avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holders were Noked Israel Ltd ($403K), Morgan Stanley ($37K) and Rhumbline Advisers ($23K).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 4,435 shares bought and 8,100 shares sold, net −3,665 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Noked Israel Ltd | 0.08% | No change | 198,888 | $403K |
| Morgan Stanley | 0.00% | Reduce -30.6% | 18,351 | $37K |
| Rhumbline Advisers | 0.00% | Add +68.0% | 10,954 | $23K |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.